1. ATIM-28. PHASE II TRIAL OF AV-GBM-1 (AUTOLOGOUS DENDRITIC CELLS LOADED WITH TUMOR ASSOCIATED ANTIGENS) AS ADJUNCTIVE THERAPY FOLLOWING SURGERY PLUS CONCURRENT CHEMORADIATION IN NEWLY DIAGNOSED GBM PATIENTS. (11th November 2019) Authors: Bota, Daniela; Taylor, Thomas; Picconi, David; Duma, Christopher; Aiken, Robert; LaRocca, Renato; Xiao-Tang, Kong; Fu, Beverly; Alsharif, Mohamad; Hsieh, Candace; Nistor, Gabriel; Dillman, Robert Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ATIM-42. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: OS CORRELATIONS WITH INITIAL AND MAXIMUM CD4+T LYMPHOCYTE COUNT IN THE PERIPHERAL BLOOD. (11th November 2019) Authors: Bota, Daniela; Taylor, Thomas; Xiao-Tang, Kong; Fu, Beverly; Alsharif, Mohamad; Pretto, Chrystel; Strik, Ankie; Schijns, Virgil; Stathopoulos, Apostolos Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CTIM-09. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: VACCINE OVERALL SURVIVAL IN BEVACIZUMAB NAIVE AND BEVACIZUMAB RESISTANT PATIENTS. (9th November 2020) Authors: Bota, Daniela; Taylor, Thomas; Kong, Xiao-Tang; Fu, Beverly; Hsu, Frank; Strik, Ankie; Schijns, Virgil; Stathopoulos, Apostolos Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Discovery of CC bond-forming and bond-breaking radical enzymes: enabling transformations for metabolic engineering. (October 2020) Authors: Fu, Beverly; Balskus, Emily P Journal: Current opinion in biotechnology Issue: Volume 65(2020) Page Start: 94 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. RARE-36. BORTEZOMIB WOKE UP A PATIENT WITH ANTI-NMDA RECEPTOR ENCEPHALITIS REFRACTORY TO STANDARD THERAPY AND LONG TERM FOLLOW-UP. (11th November 2019) Authors: Xiao-Tang, Kong; Groysman, Leonid; Dastur, Cyrus; Fu, Beverly; Bota, Daniela Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗